Network origin in Patrick T Gunning first degree
Entity | Entity type | Industry | |
---|---|---|---|
Janpix Holdings, Inc.
Janpix Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Janpix Holdings, Inc. engages in provision of research and experimental development on biotechnology. The company was founded by Patrick T. Gunning and Cortes Pierre and is headquartered in Cambridge, MA.
3
| Holding Company | Miscellaneous Commercial Services | 3 |
Dalriada Therapeutics, Inc.
Dalriada Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Dalriada Therapeutics, Inc. provides drug and medicinal chemistry, and intellectual property services for developing small molecule therapies. It offers covalent inhibitor development, internal R & D, program management, and IP support. The company was founded by Patrick Gunning and is headquartered in Mississauga, Canada.
1
| Holding Company | Miscellaneous Commercial Services | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Patrick T Gunning via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Epoch Biosciences, Inc.
Epoch Biosciences, Inc. Medical SpecialtiesHealth Technology Epoch Biosciences, Inc. manufactures and develops molecular tools for genetic analysis. Its technology has numerous applications including the detection of inherited diseases and single nucleotide polymorphisms to identify individuals at risk for disease or adverse drug reactions and gene expression measurement. The company was founded in 1985 and is headquartered in Bothell, WA. | Medical Specialties | President | |
COMPUGEN LTD. | Biotechnology | Director/Board Member | |
ANTHERA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
REALM THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
Lyric Pharmaceuticals, Inc.
Lyric Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA. | Pharmaceuticals: Major | Chairman | |
Imperial College London | College/University | Undergraduate Degree | |
Index Ventures SA
Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland. | Investment Managers | Private Equity Investor Private Equity Analyst | |
Massachusetts Institute of Technology | College/University | Doctorate Degree | |
New York University | College/University | Masters Business Admin | |
University of California, Davis | College/University | Graduate Degree | |
University of California San Diego | College/University | Undergraduate Degree | |
Bay City Capital LLC
Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Investment Managers | Director of Finance/CFO | |
University College London | College/University | Doctorate Degree | |
Reedland Capital Partner
Reedland Capital Partner Investment ManagersFinance Part of Paradox Holdings, Inc., Reedland Capital Partner provides investment advice. The company is based in Mill Valley, CA. The CEO of the company is Robert Schachter. | Investment Managers | Corporate Officer/Principal | |
ESSA PHARMA INC. | Pharmaceuticals: Major | Director/Board Member | |
Nuvelution Pharma, Inc.
Nuvelution Pharma, Inc. BiotechnologyHealth Technology Nuvelution Pharma, Inc. provides solutions for R&D companies in the pharmaceutical and biotech industries. The firm leverages its knowledge, experience and relationships in the Pharma and Biotech industries to deploy capital in risk-sharing collaborations with companies where product development can be facilitated by both capital and human resources, making this model an essential tool for pharma and biotech companies to bring products to the market. The company was founded by Sanford S. Zweifach and is headquartered in South San Francisco, CA. | Biotechnology | Founder | |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Investment Managers | Private Equity Investor Founder | |
Gadeta BV
Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Medical Specialties | Director/Board Member | |
Fore Biotherapeutics, Inc.
Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Director/Board Member | |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Biotechnology | Chairman | |
Palladio Biosciences, Inc.
Palladio Biosciences, Inc. BiotechnologyHealth Technology Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA. | Biotechnology | Director/Board Member | |
Imidomics, Inc.
Imidomics, Inc. BiotechnologyHealth Technology Imidomics, Inc. is an American biotechnology company that focuses on discovering and developing new medicines for immune-mediated inflammatory diseases (IMIDs). The company is based in an undisclosed location. Imidomics has access to the IMID-biobank, which includes real-world data from clinical records and biological samples from over 17,000 IMID patients and control subjects across six indications. The company utilizes a proprietary digital bioinformatics portal called the Imidomics Precision Discovery Platform to generate novel insights into disease mechanisms and identify potential new drug targets. The company was founded in Barcelona in 2015 by Dr. Sara Marsal and Dr. Richard M. Myers. The CEO of the company is Fred Bernard Craves. | Biotechnology | Corporate Officer/Principal | |
Pathway Diagnostics Ltd.
Pathway Diagnostics Ltd. Medical DistributorsDistribution Services Pathway Diagnostics Ltd. provides clinical diagnostic products and medical instrumentation services. Its products include haemostasis, autoimmune and allergy, complement system, bone and cartilage, metabolic syndrome, organ injury, oncology and toxicology. The company was founded in 1999 and is headquartered in Dorking, the United Kingdom. | Medical Distributors | Chief Executive Officer | |
Kaerus Bioscience Ltd. | Chairman | ||
VaxNewMo LLC
VaxNewMo LLC BiotechnologyHealth Technology VaxNewMo LLC is an early-stage biotechnology company based in St. Louis, MO. The company is developing polysaccharide conjugate vaccines against serious bacterial threats using its proprietary bioconjugation platform. The omniose bioconjugate vaccine platform enables the precise enzymatic attachment of virtually any bacterial polysaccharide antigen to engineered carrier proteins within a single E. coli cell. The company is breaking through the barrier of limited range of bacterial vaccines that can be developed, while leveraging the already established benefits of bioconjugation. The company was founded by Mario Feldman, Christian Harding, and Christine Szymanski. Michael Timothy Cooke has been the CEO of the company since 2022. | Biotechnology | Chairman | |
Vaderis Therapeutics AG
Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | Biotechnology | Chairman | |
Syndexis SARL | Director/Board Member | ||
CARISMA THERAPEUTICS, INC. | Biotechnology | Chairman |
Statistics
International
United States | 21 |
United Kingdom | 7 |
Switzerland | 5 |
Canada | 3 |
Israel | 2 |
Sectoral
Health Technology | 22 |
Consumer Services | 6 |
Finance | 6 |
Distribution Services | 2 |
Operational
Director/Board Member | 18 |
Chairman | 7 |
Independent Dir/Board Member | 6 |
Chief Executive Officer | 5 |
Private Equity Investor | 4 |
Most connected contacts
Insiders | |
---|---|
Sanford Zweifach | 22 |
Giovanni Mariggi | 9 |
Roman J. Fleck | 8 |
Diana Kraskouskaya | 1 |
- Stock Market
- Insiders
- Patrick T Gunning
- Company connections